Global Theranostics Market - Strategic Insights and Forecasts (2026-2031)

Global Theranostics Market is projected to register a strong CAGR during the forecast period (2026-2031).

Market Overview

Cancer incidence provides the largest underlying demand pool. IARC estimates that 20.6 million people were diagnosed with cancer globally in 2024, with lung, breast, colorectal, and prostate cancers accounting for the largest case volumes among the major cancer types. IARC projects 34.4 million cancer cases by 2050, although the pace of theranostics adoption will depend on diagnostic access, treatment eligibility, reimbursement, and nuclear medicine capacity rather than cancer incidence alone.

Commercial value is distributed across several linked activities. Diagnostic companies supply PET and SPECT systems and imaging agents, pharmaceutical companies develop targeted therapies, radiopharmaceutical manufacturers manage isotope production and distribution, while hospitals and nuclear medicine centers provide treatment capacity. The model also creates demand for companion diagnostics, molecular testing, dosimetry, specialized pharmacy services, radiation safety infrastructure, and trained personnel.

Buyer decisions therefore extend beyond clinical efficacy. Hospitals and specialty cancer centers must consider isotope availability, treatment scheduling, radiation-handling capability, reimbursement, regulatory compliance, scanner capacity, and the reliability of time-sensitive radiopharmaceutical deliveries. Suppliers with control over manufacturing, isotope access, diagnostic agents, or treatment networks can capture value across several stages of the pathway.

Key Market Indicators

Market Drivers

Expansion of PSMA-directed prostate cancer pathways. FDA expanded Pluvicto's indication in March 2025 to PSMA-positive metastatic castration-resistant prostate cancer patients previously treated with an androgen receptor pathway inhibitor who may delay taxane chemotherapy. Patient selection requires an approved PSMA PET product, linking diagnostic imaging directly to treatment eligibility. The FDA reported median radiographic progression-free survival of 9.3 months with Pluvicto versus 5.6 months for the comparator arm in PSMAfore. This broader indication increases the addressable treatment pathway while reinforcing demand for PSMA imaging agents.

Growth in targeted radiopharmaceutical therapy capacity. Radioligand therapy requires specialized manufacturing, isotope supply, quality controls, transport, and treatment-center coordination. Novartis expanded its US RLT manufacturing network with an Indianapolis facility that increased stated production capacity to 250,000 doses in 2024. The company subsequently opened a California RLT facility in November 2025 and identified further US investment as part of a broader infrastructure program. Capacity expansion is therefore becoming a prerequisite for converting clinical approvals into patient access.

Higher clinical use of molecularly defined treatment selection. Companion diagnostics identify patients whose tumors express a biomarker linked to treatment response. Roche's FDA-approved VENTANA MET SP44 RxDx assay, for example, identifies MET protein expression in non-squamous non-small cell lung cancer patients who may be eligible for c-Met-targeted therapy. Such testing changes the purchasing model because diagnostic laboratories and hospitals must connect biomarker testing with treatment decisions. This supports demand for immunohistochemistry, molecular imaging, sequencing, and related diagnostic services.

Broader disease investigation by radioligand developers. The commercial model is moving beyond established prostate and neuroendocrine applications. Novartis has identified investigational RLT programs spanning breast, colorectal, neuroendocrine, lung, pancreatic, and prostate cancers. Expansion into additional targets could increase utilization of PET imaging, radiopharmaceutical manufacturing, specialized treatment centers, and companion diagnostics. Commercial success will depend on whether clinical trials establish sufficient target expression, treatment benefit, safety, and reimbursement support in each disease setting.

Market Restraints and Challenges

Short half-lives and complex isotope logistics. Many diagnostic and therapeutic radionuclides impose strict timing requirements between production, labeling, shipment, and administration. This limits the ability to centralize supply without affecting delivery windows and can make manufacturing location commercially important. Curium's expansion of PET production and distribution through the Nucleis acquisition illustrates the need for regional manufacturing and distribution capacity. For hospitals, supply reliability can influence scheduling, scanner utilization, patient throughput, and treatment continuity.

Limited specialized infrastructure and workforce capacity. Theranostics requires more than a PET or SPECT scanner. Treatment centers need licensed nuclear medicine facilities, radiation protection systems, trained physicians and technologists, radiopharmacy capability, appropriate treatment rooms, and procedures for radioactive waste. India's Atomic Energy Regulatory Board requires regulatory consent for nuclear medicine facilities and provides specific requirements covering high-dose therapy, suppliers, facility design, radiation safety, and radioactive-material transport. These requirements can slow expansion where trained staff and compliant facilities are limited.

Radioisotope supply concentration and capacity risk. Treatment growth can expose the market to constraints in isotope production, target material, reactor or accelerator availability, and specialized processing. ITM and the Institut Laue-Langevin extended their collaboration in 2025, giving ITM priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor for non-carrier-added lutetium-177 production. Such arrangements demonstrate why access to isotope infrastructure remains a strategic consideration for therapeutic radiopharmaceutical suppliers.

Regulatory and reimbursement complexity. Theranostic products can require evidence for both diagnostic performance and therapeutic safety and efficacy. Health Canada classifies radiopharmaceuticals under Schedule C of the Food and Drugs Act and requires market authorization based on safety, efficacy, and quality. Brazil separately regulates radiopharmaceutical registration, importation, and quality control through ANVISA. Differences between regulatory systems increase development and market-entry requirements for suppliers seeking global commercialization.

Major Segment Analysis

Oncology

Oncology represents the most commercially important disease category because theranostics has the clearest established link between molecular imaging, patient selection, and targeted treatment in cancer care. Prostate cancer is particularly relevant because PSMA PET imaging can identify eligible patients for PSMA-directed radioligand therapy. Telix's Illuccix received FDA approval for prostate cancer imaging and later received an expanded US indication for selecting patients for PSMA-directed therapy.

Purchasing decisions in oncology depend on diagnostic accuracy, treatment efficacy, isotope availability, throughput, safety, and reimbursement. Hospitals also need coordinated workflows between imaging, pathology, oncology, nuclear medicine, and pharmacy teams. The segment's economics increasingly favor suppliers able to connect diagnostic agents with therapeutic products, manufacturing capacity, and clinical support. Prostate cancer therefore provides a useful commercial model for the wider oncology theranostics pipeline, although other applications must establish comparable target specificity and treatment evidence before achieving similar adoption.

Regional Analysis

North America has the strongest established commercial infrastructure for theranostics, supported by FDA approvals, large oncology centers, pharmaceutical investment, and specialized radiopharmaceutical manufacturing. The US market is particularly important for PSMA PET and radioligand therapy, with FDA expansion of Pluvicto in 2025 broadening treatment eligibility. Novartis has continued to add US manufacturing capacity, while Lantheus and Telix support the diagnostic side of prostate cancer theranostics. Canada maintains a separate regulatory pathway for radiopharmaceutical drugs and requires authorization before commercial sale.

Europe combines established nuclear medicine expertise with fragmented national approval, reimbursement, and healthcare procurement systems. Curium expanded its European PET manufacturing and distribution network through the 2025 acquisition of Nucleis, strengthening access across Benelux and Germany. Telix also secured additional European approvals for Illuccix during 2025. Supply availability remains a practical constraint in some markets, particularly where demand for PSMA PET exceeds local production capacity.

Asia Pacific offers a broad patient base and expanding nuclear medicine capacity, but adoption differs sharply between countries. Japan and China have substantial pharmaceutical and medical technology infrastructure, while India combines growing cancer needs with a regulatory framework covering nuclear medicine facilities, radiation safety, suppliers, and radioactive-material transport. Telix's January 2026 filing acceptance for Illuccix in China indicates the commercial importance of expanding PSMA imaging into the Chinese market.

Latin America, the Middle East and Africa remain more dependent on specialist centers, imported radiopharmaceuticals, regulatory approvals, and investment in nuclear medicine infrastructure. Brazil is an important regional market because ANVISA has a defined regulatory framework for radiopharmaceuticals. Telix's 2025 Brazilian approval for Illuccix provides evidence of commercial expansion of PSMA PET beyond North America, Europe, and selected Asia Pacific markets.

Competitive Landscape

Competition spans pharmaceutical developers, radiopharmaceutical specialists, diagnostic suppliers, imaging manufacturers, and companies controlling isotope production or distribution. Novartis AG has built scale around radioligand therapy through Pluvicto, Lutathera, manufacturing capacity, and pipeline expansion. Telix Pharmaceuticals Limited combines PSMA imaging with a broader therapeutic pipeline, while Lantheus Holdings, Inc. has an established position in molecular imaging.

Roche Holding AG competes through companion diagnostics and pathology, whereas GE HealthCare Technologies Inc. supplies molecular imaging systems and radiopharmaceutical imaging agents. Curium Pharma, Eckert & Ziegler SE and ITM Isotope Technologies Munich SE address isotope, radiopharmaceutical, and supply-chain requirements. Abbott Laboratories, Bayer AG and Curium Pharma broaden competition across diagnostics, targeted therapies, and nuclear medicine infrastructure.

Recent Developments

• August 2026: Curium agreed to acquire Lantheus for up to $8 billion, combining radiopharmaceuticals with targeted radioligand therapy and creating a theranostics platform spanning PET, SPECT, and treatment.

• January 2026: Telix announced that China's NMPA had accepted the Illuccix application for prostate cancer imaging. The filing included Phase 3 data and supports expansion of PSMA-PET access into a large oncology market.

• November 2025: Novartis opened a radioligand therapy manufacturing facility in Carlsbad, California. The site became the company's third US RLT manufacturing facility and was intended to add supply capacity for future demand.

• April 2025: Curium completed its acquisition of Nucleis, adding PET manufacturing capability and a 32-site Western European distribution network. The transaction also expanded Curium's CDMO capacity for PET tracers in oncology, neurology, and cardiology.

Regulatory and Policy Environment

Regulation affects the market at both the product and facility levels. In the United States, FDA approval can define not only the therapeutic indication but also the diagnostic evidence needed to select patients. The 2025 Pluvicto expansion explicitly requires PSMA PET selection, reinforcing the regulatory connection between imaging and treatment. This favors companies capable of coordinating diagnostic and therapeutic development rather than treating them as separate product categories.

Facility-level regulation is equally important because radiopharmaceuticals involve ionizing radiation and radioactive materials. India's AERB requires nuclear medicine facilities to obtain regulatory consent and maintains requirements for radiation protection, radioactive-waste disposal, facility design, supplier controls, and safe transport. Canada applies Schedule C requirements to radiopharmaceuticals, while Brazil maintains dedicated registration and GMP provisions. These frameworks raise compliance costs but also create barriers that can protect qualified suppliers from rapid market entry by less specialized competitors.

Outlook and Strategic Implications

From 2026 to 2031, commercial development will depend less on the availability of isolated imaging or therapy technologies and more on the ability to build complete diagnostic-to-treatment pathways. Prostate cancer provides the clearest model because PSMA imaging identifies patients and radioligand therapy subsequently acts on the same target. Expansion into breast, colorectal, lung, pancreatic, and neuroendocrine cancers could broaden the opportunity, but each indication will require clinical evidence, reliable isotope supply, regulatory approval, and adequate treatment infrastructure.

Manufacturing scale will remain a strategic differentiator. Novartis' investment in multiple RLT facilities, Curium's expansion of PET production, and ITM's effort to secure lutetium-177 irradiation capacity all indicate that supply infrastructure can influence commercial access as strongly as product approval.

For suppliers, the strongest opportunities are likely to sit at interfaces between diagnostics, therapeutics, isotope supply, and clinical delivery. Hospitals and investors will need to assess treatment capacity, isotope security, reimbursement, regulatory requirements, and patient-selection workflows rather than equipment or medicines in isolation. Companies that can secure reliable radionuclide supply, establish regional manufacturing, support companion diagnostics, and obtain approvals across multiple geographies should be better positioned to convert clinical advances into recurring commercial demand.

Global Theranostics Market Scope: